Text Size

ECT Schizophrenia Serotonin Study

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by Sha’ar Menashe Mental Health Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Sha’ar Menashe Mental Health Center
ClinicalTrials.gov Identifier:
NCT00278668
First received: January 16, 2006
Last updated: May 20, 2008
Last verified: May 2008
History of Changes
  Purpose

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT


Condition Phase
Schizophrenia
 Phase 1

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
Drug Information available for: Serotonin
U.S. FDA Resources

Further study details as provided by Sha’ar Menashe Mental Health Center:

Estimated Enrollment: 15
Study Start Date: October 2006
Estimated Study Completion Date: October 2006
Detailed Description:

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).

Ages 18 -55 Men and/or women -

Exclusion Criteria:

  1. History of neurological disorders, active substance abuse in the previous 3 months.
  2. Estimated IQ less then 70.
  3. SSRIs treatment 4 weeks prior to the study.

  4. Any subject suffering from inflammatory fever disease will be excluded from the study.

    -

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00278668

Contacts
Contact: Avi Peled, MD 972522844050 av_peled@netvision.net.il

Sponsors and Collaborators
Sha’ar Menashe Mental Health Center
Investigators
Principal Investigator: Avi Peled, MD Shaar Menashe MHC
Principal Investigator: Ilan Modai, M.D. MHA Shaar Menashe
Principal Investigator: Moshe Rehavi, Ph.D. TAU
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00278668     History of Changes
Other Study ID Numbers: 123.ctil
Study First Received: January 16, 2006
Last Updated: May 20, 2008
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Serotonin
Serotonin Receptor Agonists
 Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013